↓ Skip to main content

Remarkable regression of massive deep vein thrombosis in response to intensive oral rivaroxaban treatment

Overview of attention for article published in Thrombosis Journal, March 2015
Altmetric Badge

Mentioned by

facebook
1 Facebook page

Citations

dimensions_citation
17 Dimensions

Readers on

mendeley
38 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Remarkable regression of massive deep vein thrombosis in response to intensive oral rivaroxaban treatment
Published in
Thrombosis Journal, March 2015
DOI 10.1186/s12959-015-0045-1
Pubmed ID
Authors

Norimichi Koitabashi, Nogiku Niwamae, Tetsuya Taguchi, Yoshiaki Ohyama, Noriaki Takama, Masahiko Kurabayashi

Abstract

Deep vein thrombosis (DVT) is a common disease and is associated with pulmonary embolism (PE). Proximal iliofemoral DVT may lead to severe PE and chronic venous insufficiency. The standard therapy for DVT is anticoagulant therapy using heparin and a vitamin K antagonist, but a recent clinical study showed that rivaroxaban, an oral Xa inhibitor, was comparable to standard therapy and had less bleeding complications. Intensive high-dose anticoagulation is recommended during the initial 3 weeks of DVT treatment. The present report describes a case of a 77-year-old male showing a remarkable regression of DVT in response to rivaroxaban treatment within the initial 3 weeks of therapy and who did not experience any adverse events. His DVT was massive and was accompanied by proximal iliofemoral vein thrombus and iliac vein compression syndrome. Rivaroxaban, especially in intensive high-dose treatment, might be a safe and effective therapeutic choice for massive DVT.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 3%
United States 1 3%
Unknown 36 95%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 8 21%
Other 5 13%
Student > Bachelor 5 13%
Student > Master 3 8%
Student > Doctoral Student 2 5%
Other 7 18%
Unknown 8 21%
Readers by discipline Count As %
Medicine and Dentistry 22 58%
Biochemistry, Genetics and Molecular Biology 1 3%
Mathematics 1 3%
Pharmacology, Toxicology and Pharmaceutical Science 1 3%
Social Sciences 1 3%
Other 3 8%
Unknown 9 24%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 March 2015.
All research outputs
#22,759,452
of 25,373,627 outputs
Outputs from Thrombosis Journal
#375
of 406 outputs
Outputs of similar age
#238,594
of 277,672 outputs
Outputs of similar age from Thrombosis Journal
#8
of 9 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 406 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.0. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 277,672 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one.